Delaware | 94-3023969 | |
(State or Other Jurisdiction of Incorporation) | (I.R.S. Employer Identification No.) |
Exhibit No. | Description | |
99.1 |
PDL BIOPHARMA, INC. | ||
(Company) | ||
By: | /s/ John P. McLaughlin | |
John P. McLaughlin | ||
Chief Executive Officer |
Exhibit No. | Description | |
99.1 |
G)E
M4WI.5&-Z:V,Y9"(_/B \>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE
M=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C M8S V," V,2XQ,S0W
M-S D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
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M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z& XV"]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7SO_P">C_V]/^4?_E$O_@=.HO?3_P"[O_TYWD__ *B_^TZYZYA_>'_Z
M?#S?_P!0G_:%;=5*^YKZA;KWOW7NO>_=>Z][]U[KZ'_\B[_MUA\7/_*V_P#P
M1?;OOE_]XC_I\7.'_4)_V@VW73S[O'_3GN4/^HO_ +3;GJVOW"O4T]>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U4]_/5Q.=S7\GW^8C1[\1_XQ"U5< A98C\$J>JN/S5@R-1E8#JCR5SAM//7+FW\
MR;/)_B\RT9"06BD'QQ/Z,A_)E*NM5923)^PIT*^O>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z^9Q_,Q_[>#?,G_P 6([/_ />FKO?6?VE_Z=ER)_TJ
M[?\ ZMCKDY[L?]/,YZ_Z6EQ_U1'/]^Z]U] C^7]_
M+^^$78'PB^*V]][_ !6Z-W5N_=71O7F
N.G,G_ "L6_P#_ #VS_P#5UN@E
M]G?1+U[W[KW7O?NO=>]^Z]U]4_H'_F1'2G_B).N/_>.PWOC?S+_RL>__ //;
M/_U=;KL5RU_RKFP?\\4'_5I>A;]DO1WU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW12OF%\)N@?G!UI/UQWCM.'(/2I4S;/WSB4IJ'?FP,
MK4(@;)[3W ]//+2I,\,9JJ*59J"N6-!40R:$*C7D;G_F7V]W9=UY>O2H-!+"
MU3#,H_#(E0#2ITL*.E3I85-05SQR!RU[@[2VU'Q^X-M[APU5'6XK-87+4L=;CLE05<):.>EJZ6971A
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M&Z?\E/^:\G_'SUL+_RAO\ LFS>_P#XG'
N.G,G_ "L6_P#_ #VS_P#5UN@E]G?1
M+U[W[KW7O?NO=>]^Z]U]4_H'_F1'2G_B).N/_>.PWOC?S+_RL>__ //;/_U=
M;KL5RU_RKFP?\\4'_5I>A;]DO1WU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U27_/)^"E+\K_BSDNT-G8=)^[?CGCLSO;;
M